Evidence map›Paper›PMID 32536827›Full record

ReviewClinical and molecular allergy : CMA2020

New perspectives in allergen specific immunotherapy driven by big trials with house dust mite sublingual SQ

Gianfranco Vitiello, Lucia Maltagliati, Oliviero Rossi

Open access · goldAbstract readReview
In one paragraph

Review in Clinical and molecular allergy : CMA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Gianfranco VitielloExperimental and Clinical Medicine Department, University of Firenze, Largo Brambilla 3, 50100 Florence, Italy.ORCID 0000-0003-4196-3527
Lucia MaltagliatiExperimental and Clinical Medicine Department, University of Firenze, Largo Brambilla 3, 50100 Florence, Italy.
Oliviero RossiSOD Immunoallergologia, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
University of Florence · ITAzienda Ospedaliero-Universitaria Careggi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

House-dust mites (HDM) allergy is the prevailing condition in subjects allergic to inhalants. Clinical studies with HDM extracts-either subcutaneous (SCIT) or sublingual (SLIT) have long been characterized by small sample size, varying allergen doses, and poorly defined endpoints assessing disease severity. In the last decade, well-designed, randomized, controlled studies recruiting thousands of patients have been conducted with newly developed HDM sublingual tablets (SQ

Indexed as

Allergen immunotherapy (AIT)Allergic asthmaAsthma guidelinesBig trialsFast-dissolving tabletHouse-dust mite

Identifiers

PMID32536827
PMCPMC7288442
OpenAlexW3035586057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.